SHBG Interpretation by Decade of Life: Normal Ranges, Optimal Levels, and What Your Number Actually Means

What SHBG Is and Why It Matters More Than Most Doctors Explain

SHBG is a glycoprotein synthesized almost entirely in the liver. It circulates in the blood and binds sex steroids with high affinity, creating a reservoir of hormonally inactive bound hormone. Only the unbound (free) fraction and the loosely albumin-bound fraction can enter cells and activate androgen or estrogen receptors.

The Binding Hierarchy

Testosterone, dihydrotestosterone (DHT), and estradiol all compete for the same binding site on SHBG, but with different affinities. DHT binds most tightly (roughly 3-fold higher affinity than testosterone), estradiol binds with moderate affinity, and DHEA-S barely binds at all [1]. When SHBG is high, the free fractions of testosterone and estradiol shrink. When SHBG is low, free fractions expand, which can be either beneficial or problematic depending on baseline hormone levels and the clinical picture.

The Free Testosterone Calculation

Measured free testosterone by equilibrium dialysis costs more than $200 at most reference labs and has a 48-to-72-hour turnaround. The Vermeulen equation, which uses total testosterone, albumin (assumed 4.3 g/dL), and SHBG, produces a calculated free testosterone that correlates well with dialysis measurements [2]. Most telehealth and outpatient hormone panels rely on this calculated value. SHBG is therefore not a standalone test. It is the essential denominator in the free-hormone calculation.

Why Reference Ranges Are Misleading Without Age Context

Most lab reports print a single adult male range (roughly 10 to 57 nmol/L) or a single adult female range (roughly 18 to 144 nmol/L). Both are too wide to be clinically actionable. A 28-year-old man with an SHBG of 55 nmol/L and a total testosterone of 600 ng/dL has a calculated free testosterone well below the 2% threshold that many endocrinologists use as a functional floor. A 68-year-old man with the same numbers may simply reflect normal aging physiology. Context is everything [3].

SHBG by Decade in Men

Men's SHBG follows a predictable age trajectory: relatively low and stable from the 20s through the 30s, then rising gradually from the 40s onward as testicular testosterone output declines and hepatic SHBG synthesis increases. The Massachusetts Male Aging Study (MMAS), a community-based prospective cohort, documented a 1.6% per-year rise in SHBG in men aged 40 to 70 [4].

Men in Their 20s and 30s (Ages 20 to 39)

Expected SHBG: 13 to 40 nmol/L.

This is the decade when low SHBG is the more common clinical problem. Obesity, metabolic syndrome, and non-alcoholic fatty liver disease all suppress hepatic SHBG production. The Framingham Heart Study offspring cohort found that men with BMI above 30 had SHBG levels roughly 30 to 40% lower than normal-weight peers [5]. An SHBG below 15 nmol/L in a man under 40 with central adiposity is a metabolic warning sign, not just a hormone imbalance.

Conversely, SHBG above 45 nmol/L in a lean 25-year-old man with low libido and total testosterone around 400 ng/dL warrants calculation of free testosterone. The free T may fall below the 50 to 70 pg/mL range that the American Urological Association cites as a functional lower limit [6].

Men in Their 40s (Ages 40 to 49)

Expected SHBG: 18 to 50 nmol/L.

The 40s are a transition decade. Mean SHBG climbs modestly, but the more clinically significant change is the beginning of the hypothalamic-pituitary-gonadal axis slowing. A man with an SHBG of 48 nmol/L, total testosterone of 450 ng/dL, and symptoms of low androgen delivery (morning wood absent, libido reduced, fatigue) has a calculated free T of approximately 60 to 65 pg/mL, right at the lower boundary of normal. This cohort often presents to primary care with "normal labs" but genuine functional androgen insufficiency.

Men in Their 50s (Ages 50 to 59)

Expected SHBG: 25 to 60 nmol/L.

By the mid-50s, roughly 20 to 30% of men meet criteria for late-onset hypogonadism by total testosterone alone, but that figure rises to 35 to 40% when free testosterone is calculated using measured SHBG [7]. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states: "In men in whom total testosterone concentration is in the low-normal range (200 to 400 ng/dL), we suggest measuring free testosterone by equilibrium dialysis or calculating free testosterone using total testosterone and SHBG" [8].

Thyroid function becomes more relevant in this decade. Hyperthyroidism raises SHBG directly via hepatic transcription upregulation; subclinical hyperthyroidism (TSH 0.1 to 0.4 mIU/L) can push SHBG 15 to 25% above an individual's baseline [9].

Men in Their 60s and Beyond (Ages 60+)

Expected SHBG: 30 to 80 nmol/L.

The upper end of the male reference range is dominated by men over 60. SHBG above 60 nmol/L in this age group is not automatically pathological, but it does compress the free testosterone fraction significantly. The European Male Aging Study (EMAS), which enrolled 3,369 community-dwelling men aged 40 to 79, found that the combination of a calculated free testosterone below 220 pmol/L and three or more sexual symptoms defined symptomatic late-onset hypogonadism better than total testosterone alone [7].

In men on testosterone replacement therapy (TRT), high SHBG may necessitate shorter injection intervals or higher doses to maintain adequate free testosterone trough levels. Anastrozole, sometimes prescribed off-label to reduce estradiol, also suppresses SHBG modestly (roughly 10 to 15%) by lowering estrogenic stimulation of hepatic synthesis [10].

SHBG by Decade in Women

Women's SHBG story is more complex because estrogen itself stimulates hepatic SHBG production, meaning levels swing dramatically across the reproductive lifespan and with the route of hormone administration.

Women in Their 20s and 30s (Ages 20 to 39)

Expected SHBG: 40 to 120 nmol/L.

Young women on combined oral contraceptives (COCs) containing ethinyl estradiol routinely have SHBG levels of 150 to 250 nmol/L, 3-to-6-fold above baseline [11]. This suppression of free testosterone can persist for 6 to 12 months after COC discontinuation, a phenomenon documented in a 2006 study by Panzer et al. Published in the Journal of Sexual Medicine that measured SHBG in women before, during, and after COC use [11].

Women with polycystic ovary syndrome (PCOS) show the opposite pattern. Hyperinsulinemia suppresses hepatic SHBG, pushing levels below 30 nmol/L in many cases. The Androgen Excess and PCOS Society notes that low SHBG amplifies free androgen exposure and contributes to the hyperandrogenic phenotype even when total testosterone is only mildly elevated [12].

Women in Their 40s: Perimenopause (Ages 40 to 49)

Expected SHBG: 40 to 110 nmol/L.

The perimenopause transition is characterized by erratic estradiol fluctuation. During high-estradiol surges (common in early perimenopause), SHBG rises transiently. As cycles become anovulatory and mean estradiol declines, SHBG drifts downward. Women who enter perimenopause overweight often have chronically suppressed SHBG, which paradoxically makes them less symptomatic from the androgen perspective but more metabolically vulnerable.

Women at Menopause and Beyond (Ages 50+)

Expected SHBG: 30 to 130 nmol/L (wide range; route of HRT is the dominant modifier).

Post-menopausal SHBG averages roughly 50 to 80 nmol/L in untreated women, lower than peak reproductive years because endogenous estrogen is gone. The route of hormone therapy dramatically changes this picture.

Oral estradiol or conjugated equine estrogen passes through the liver (first-pass effect) and raises SHBG by 50 to 100% compared to baseline [13]. Transdermal estradiol at equivalent systemic doses bypasses first-pass hepatic metabolism and produces little to no change in SHBG [13]. This difference matters for women with already-low SHBG and androgen excess symptoms, and it matters for women on TRT who do not want their free testosterone suppressed by a rising SHBG driven by oral estrogen.

The Menopause Society (formerly NAMS) position statement on hormone therapy notes that transdermal estrogen is preferred in women with metabolic syndrome partly because it avoids the SHBG-elevating and triglyceride-raising effects of oral estrogen [14].

What "Optimal" SHBG Actually Means

No single number defines optimal SHBG. The concept of an optimal range is sex-specific, age-specific, and goal-specific. Patterns from large cohort studies suggest approximate functional targets.

In Men

A practical framework for men in clinical practice:

• SHBG <15 nmol/L: investigate for insulin resistance, liver disease, hypothyroidism; free testosterone may be elevated even with modest total T, but the metabolic context usually dominates
• SHBG 20 to 40 nmol/L: the sweet spot for most men aged 25 to 55 who want both adequate free testosterone and a metabolic profile not dominated by insulin resistance
• SHBG 40 to 60 nmol/L: acceptable in men over 55; re-check free testosterone; consider thyroid function
• SHBG >60 nmol/L: in any symptomatic man, calculate free testosterone; if free T is below 220 pmol/L (EMAS threshold), the clinical picture supports hypogonadism workup regardless of total T

A 2022 analysis in the Journal of Clinical Endocrinology and Metabolism using the UK Biobank (N=136,291) found that men with SHBG in the highest quartile (above 55 nmol/L) had 27% higher all-cause mortality risk over a median 7.1-year follow-up compared to men in the second quartile, even after adjusting for total testosterone and BMI [15]. The association appeared driven partly by the free testosterone deficit and partly by SHBG's independent role as a biomarker of hepatic and metabolic dysfunction.

In Women

For women not on hormone therapy, an SHBG in the 50 to 120 nmol/L range in the reproductive years and 40 to 80 nmol/L post-menopause represents typical physiology. Women experiencing symptoms consistent with androgen insufficiency (low libido, fatigue, reduced muscle mass) with SHBG consistently above 120 nmol/L should have free testosterone calculated, since total testosterone may appear "normal" while the bioavailable fraction is essentially zero.

For women on transdermal testosterone therapy (off-label in the US, approved in some countries), the Endocrine Society's 2014 female androgen insufficiency statement and the Global Consensus Position Statement on Female Testosterone both recommend targeting premenopausal female free testosterone reference ranges, not male ranges [16]. SHBG monitoring is essential in this context because oral estrogen co-administration can double SHBG and cut free testosterone to sub-therapeutic levels.

What Moves SHBG: A Metabolic and Pharmacological Overview

Factors That Lower SHBG

Insulin is the most potent physiological suppressor of SHBG. High fasting insulin reduces hepatic SHBG transcription via the hepatocyte nuclear factor 4-alpha (HNF-4alpha) pathway [17]. Weight loss of 10% body weight can raise SHBG by 15 to 25% in obese individuals, effectively improving the free testosterone balance without any exogenous hormone.

Other suppressors include:

• Exogenous androgens (testosterone, DHEA, danazol, 17-alpha alkylated oral steroids)
• High-dose progestins (medroxyprogesterone acetate more than micronized progesterone)
• Glucocorticoids at supraphysiologic doses
• Hypothyroidism (TSH above 4.5 mIU/L)
• Growth hormone excess (acromegaly)

Factors That Raise SHBG

Oral estrogens are the most potent pharmacological elevators. Natural elevators include aging itself, hyperthyroidism, prolonged caloric restriction (SHBG can rise 20 to 30% with extended fasting or very-low-calorie dieting), and hepatic inflammation that paradoxically increases synthesis in some forms of acute hepatitis [18].

Medications that raise SHBG include:

• Oral contraceptives (ethinyl estradiol-containing formulations most potent)
• Anticonvulsants (phenytoin, carbamazepine) via CYP induction and hepatic synthesis upregulation
• Tamoxifen (selective estrogen receptor modulator acting agonistically in the liver)

SHBG and Metabolic Disease Risk: Beyond Hormone Delivery

SHBG is not merely a passive carrier protein. Low SHBG independently predicts type 2 diabetes risk. The Nurses' Health Study (N=359 cases, 359 controls) found that women in the lowest SHBG quartile (below 37 nmol/L) had a 6.1-fold higher risk of developing type 2 diabetes over 10 years compared to women in the highest quartile, even after adjusting for BMI and family history [19].

In men, a meta-analysis of 11 prospective studies (N=6,427) published in BMJ in 2011 concluded that each 10 nmol/L increase in SHBG was associated with a 23% lower risk of type 2 diabetes (RR 0.77, 95% CI 0.72 to 0.83) [20]. This association is bidirectional: insulin suppresses SHBG, and low SHBG may itself worsen metabolic signaling through mechanisms still under investigation.

Clinicians ordering SHBG only to contextualize testosterone are therefore leaving interpretive value on the table. A persistently low SHBG, especially below 20 nmol/L in either sex, should prompt a fasting insulin level, HOMA-IR calculation, and lipid panel if these are not already in the workup [20].

SHBG in Hormone Therapy Monitoring

Men on TRT

Testosterone cypionate or enanthate administered every 7 to 14 days raises total testosterone but does not reliably raise free testosterone if SHBG remains very high. Men with SHBG above 50 nmol/L on weekly injections may respond better to twice-weekly dosing of the same total weekly dose, producing higher trough free T without higher peak total T. Testosterone pellets produce stable serum levels and tend to be more effective at maintaining adequate free testosterone in high-SHBG men than biweekly or monthly injection regimens [21].

Women on HRT and Testosterone

Women receiving oral estrogen (any form) alongside transdermal testosterone should have SHBG checked at 6 to 8 weeks after any dose change. The SHBG rise from oral estrogen can be steep enough to completely negate the testosterone dose. Switching to transdermal estradiol (patches, gels, sprays) is the most effective single intervention when oral estrogen is the identified SHBG driver [13].

Practical Lab Ordering and Interpretation Checklist

Before interpreting any SHBG result, confirm:

1. The assay method (chemiluminescence immunoassay vs. Mass spectrometry; values can differ by 10 to 20% between platforms)
2. Time of collection (SHBG is not time-sensitive the way cortisol is, but should be consistent across serial measurements)
3. Concurrent medications (any oral estrogen or androgen in the past 4 weeks)
4. Fasting status (not required, but relevant when interpreting alongside fasting insulin)
5. Liver function markers (AST, ALT, GGT), since significant hepatocellular disease alters SHBG production unpredictably

Serial SHBG trending matters more than any single reading. A decline from 45 to 22 nmol/L in a 42-year-old woman over 18 months, without a medication change, should raise concern for progressive insulin resistance or an occult androgen excess state well before fasting glucose becomes abnormal.